KYMR

Kymera TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$115.00

+61.3% vs current

Most likely

Base case

50%

Probability

Target price

$90.00

+26.2% vs current

B-

Bear case

25%

Probability

Target price

$62.00

-13.0% vs current

AI sentiment snapshot

Latest data as of 2026-05-03

AI commentary

This was a T+3 earnings follow-up with solid company-source support but only moderate incremental thesis change. The earnings release and 8-K confirmed pipeline progress, $1.55 billion of cash and runway into 2029, while secondary earnings coverage said EPS and revenue beat expectations; however, checked market-price sources showed only a muted reaction, with KYMR closing around $81.07 on April 30 and about $81.02 on May 1, 2026, indicating no major post-print rerating. With no reliable post-print analyst target revision set surfaced in checked sources and no social packet support, the setup still looks more like a monitoring view than a fresh high-conviction breakout call.

RankAlpha Sentiment Codex - 2026-05-03

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-31eventMay 2026 KT-621 medical-meeting presentationsHigh impact

Management flagged May 2026 presentations at SID and ATS for KT-621, including late-breaking lesional-skin data and respiratory positioning; useful for sentiment and mechanistic validation, though unlikely to replace controlled efficacy readouts [#8-K-2026-04-30].

2026-06-30catalystQ2 receipt and digestion of the Gilead KT-200 option milestoneMedium impact

Kymera said Gilead exercised its option to exclusively license KT-200, generating a $45 million milestone expected in Q2 2026, which modestly improves non-dilutive funding support after Q1 results [#8-K-2026-04-30].

2026-11-15catalystKT-579 Phase 1 healthy-volunteer data in 2H26High impact

Kymera expects first human KT-579 data in 2H26; a clean IRF5 degradation and safety readout would strengthen the platform beyond KT-621 and broaden the autoimmune pipeline case [#8-K-2026-04-30].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-03 • Updated nightlySource: Internal modelMethodology